Diamorphine pharmacokinetics and conversion factor estimates for intranasal diamorphine in paediatric breakthrough pain:systematic review.
BMJ Support Palliat Care
; 2022 Feb 19.
Article
em En
| MEDLINE
| ID: mdl-35184039
ABSTRACT
BACKGROUND:
Intranasal diamorphine is a potential treatment for breakthrough pain but few paediatric data are available to assist dose estimation.AIM:
To determine an intranasal diamorphine dose in children through an understanding of pharmacokinetics.DESIGN:
A systematic review of the literature was undertaken to seek diamorphine pharmacokinetic parameters in neonates, children and adults. Parenteral and enteral diamorphine bioavailability were reviewed with respect to formation of the major metabolite, morphine. Clinical data quantifying equianalgesic effects of diamorphine and morphine were reviewed. REVIEW SOURCES PubMed (1960-2020); EMBASE (1980-2020); IPA (1973-2020) and original human research studies that reported diacetylmorphine and metabolite after any dose or route of administration.RESULTS:
The systematic review identified 19 studies 16 in adults and 1 in children and 2 neonatal reports. Details of study participants were extracted. Age ranged from premature neonates to 67 years and weight 1.4-88 kg. Intranasal diamorphine bioavailability was predicted as 50%. The equianalgesic intravenous conversion ratio of morphinediamorphine was 21. There was heterogeneity between pharmacokinetic parameter estimates attributed to routes of administration, lack of size standardisation, methodology and pharmacokinetic analysis. Estimates of the pharmacokinetic parameters clearance and volume of distribution were reduced in neonates. There were insufficient paediatric data to characterise clearance or volume maturation of either diamorphine or its metabolites.CONCLUSIONS:
We estimate equianalgesic ratios of intravenous morphinediamorphine 21, intravenous morphineintranasal diamorphine 11 and oral morphineintranasal diamorphine of 13. These ratios are based on adult literature, but are reasonable for deciding on an initial dose of 0.1 mg/kg in children 4-13 years.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article